Solutions - Page 14

Even as moving tariff targets and a capricious market have injected uncertainty into the operations of many biopharma players this year, it’s hard to deny the effect that President Donald Trump’s trade

Microsize, a U.S.-based CDMO that specializes in particle size reduction and control technologies, has linked with Switzerland’s Schedio Group to acquire a Lonza micronization facility for an undisclosed price.

Less than a week after Novartis unveiled a plan to establish a “flagship manufacturing hub” in North Carolina that would add 700 employees to its rolls, the Swiss drugmaker says it is

Maryland is becoming the home away from home for British drugmaker AstraZeneca. On Friday, the biopharma powerhouse upped its ante in the Old Line State, saying it will invest $2 billion to

Cdymax Pharma has been slapped with a warning letter from the FDA outlining two observations against the Bangalore, India-based API maker, both linked to testing shortfalls.

With a $140 million investment, Moderna will build a new facility at its manufacturing campus in Norwood, Massachusetts. The new plant will allow the company to execute end-to-end clinical- and commercial-stage production

Antheia is teaming up with TAPI—Teva’s active pharmaceutical ingredient and contract manufacturing business—in a bid to further commercialize its pipeline of biosynthetic drug ingredients and key start materials.

Novartis expect the expansion in North Carolina will add 700 new employees to its ranks. The manufacturing campus will span some 700,000 square feet between new and existing space, Novartis said.

Two months after Celltrion bought a U.S. manufacturing facility from Eli Lilly for $330 million, the South Korean biosimilar specialist said it will spend another 700 billion won ($478 million) to upgrade

In a bid to deepen its manufacturing foothold in the U.S., Regeneron Pharmaceuticals in April pledged production and infrastructure investments surpassing $7 billion across North Carolina and its native Empire State. Now,